Gynecological Cancers Not Tied to Severe COVID-19
The results, published online July 31 in the journal Cancer, revealed that these women had similar hospitalization rates and death as those who only had COVID-19.
Authors: Lombe D, Phiri M, Msadabwe S Abstract International travel has largely been suspended due to the COVID-19 pandemic. Due to this situation, Zambia has not been able to import radioactive isotopes for High Dose Rate (HDR) brachytherapy, Iridium 192 (I192) and this has led to suspension of treatment for patients. Cancer of the cervix is the most common cancer in Zambia and brachytherapy is a core component of the treatment armamentarium. Mitigation strategies may include external beam radiotherapy boost or hysterectomy but both systems are overburdened and fragile. PMID: 32728388 [PubMed]
Conclusion: Based on clinician responses, it appears that most practices across India have suffered a fall in patient volumes. The responses from government sectors point towards a bigger hit in this segment of practice. While the management of endometrial cancers and cervical cancers was mostly unchanged, most cases of advanced ovarian cancer received neoadjuvant chemotherapy. Cervical cancer, when managed by chemoradiation, was likely to have altered radiation schedules. PMID: 32728383 [PubMed]
Authors: Mendoza MJL, Tan HNC, Hernandez ARB, Dala BCA, Sacdalan DBL, Sacdalan DL, Cornelio GH, Ignacio JG Abstract COVID-19 has abruptly and radically changed the landscape of cancer care delivery throughout the world, including the Philippines. The Philippine General Hospital is the academic hospital of the University of the Philippines. Its cancer centre is a primary referral centre that takes care of Filipinos-many resource-constrained-that are burdened by malignancy. As the global pandemic challenges healthcare delivery, centres are forced to rethink how to care for their patients. This paper discusses how a n...
The U.S. Department of Energy's National Nuclear Security Administration (NNSA)...Read more on AuntMinnie.comRelated Reading: Imaging organizations lobby for more COVID-19 relief SNMMI 2020: AI analysis of PET could help classify prostate cancer SNMMI 2020: Researchers develop novel prostate cancer agents SNMMI 2020: PET/MRI combo tracks osteoarthritis progression SNMMI 2020: PSMA-PET/CT changes prostate cancer management
The all-cause mortality rate in cancer patients with nosocomial COVID-19 was more than double that of patients with community-acquired COVID-19.Medscape Medical News
Expert consensus guidance issued by ESMO says not to stop/delay cancer treatment that can impact survival and to stop labeling all patients with cancer as being more vulnerable to COVID-19 infectionMedscape Medical News
Authors: Nardin C, Puzenat E, Dalac S, Maubec E, Aubin F, GCC PMID: 32723105 [PubMed - as supplied by publisher]
Radiologists interpreting mammograms demonstrated a wide range of sensitivity...Read more on AuntMinnie.comRelated Reading: DBT benefits are strongest for initial breast screening Are LGBT women less likely to get mammograms? Cancer screenings drop precipitously due to COVID-19 Breast cancer on the rise in younger and older women Communication is key to timely breast biopsies
Conclusion: This study will provide comprehensive evidence for medical staff to adopt effective treatment strategies for breast cancer patients during the COVID-19 pandemic. PROSPERO registration number: CRD42020188208.
(European Society for Medical Oncology) An ESMO interdisciplinary expert consensus paper on how to manage cancer patients during the COVID-19 pandemic has been published today in Annals of Oncology, encouraging medical oncologists worldwide not to discontinue or delay any type of anti-cancer treatment that may potentially impact on overall survival. The experts also urge to stop labelling all cancer patients as vulnerable to coronavirus infection since this may lead to inappropriate care and potential negative outcomes.